VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MEDS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
MEDSDataMEDS AI, Inc.
$0.73$5M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksMEDSFinancials

DataMEDS AI, Inc. (MEDS) Income Statement

3Y historyFree accessUpdated daily

Revenue swung from $12.4M to $1.6M over the period while gross margin fell from 13.4% to negative 9.8% and operating margins remained deeply negative, suggesting the top line and cost structure have not yet stabilized.

Income StatementBalance SheetCash FlowRatios

MEDS Income Statement

Annual statement

MEDS Income Statement

DataMEDS AI, Inc. (MEDS) annual income statement — 3-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23
Sales/Revenue7.68M23.34M18.13M0
Revenue Growth %-77.47%28.73%--
Cost of Goods Sold17.87M32.98M16.36M0
COGS % of Revenue-141.3%90.25%-
Gross Profit-10.19M-9.64M1.77M0
Gross Margin %-132.74%-41.3%9.75%-
Gross Profit Growth %--645.32%--
Operating Expenses19.34M71.56M7.91M2.88M
OpEx % of Revenue-306.61%43.65%-
Selling, General & Admin20.59M71.56M6.8M2.88M
SG&A % of Revenue-306.61%37.5%-
Research & Development000375
R&D % of Revenue----
Other Operating Expenses-643.17K01.11M-375
Operating Income-29.53M-81.19M-6.15M-2.88M
Operating Margin %-384.58%-347.91%-33.9%-
Operating Income Growth %--1221.29%-113.33%-
EBITDA-27.66M-77.98M-5.03M-2.88M
EBITDA Margin %-360.2%-334.15%-27.75%-
EBITDA Growth %59.96%-1450.23%-74.63%-
D&A (Non-Cash Add-back)1.87M3.21M1.11M0
EBIT-29.21M-96.69M-6.02M-2.88M
Net Interest Income-6.76M-4.58M-831.47K-15.08K
Interest Income0000
Interest Expense6.76M4.58M831.47K15.08K
Other Income/Expense-13.89M-20.08M-711.09K-15.08K
Pretax Income-43.42M-101.27M-6.86M-2.9M
Pretax Margin %-565.48%-433.95%-37.82%-
Income Tax0000
Effective Tax Rate %0%0%0%0%
Net Income-43.37M-101.27M-6.86M-2.9M
Net Margin %-564.77%-433.95%-37.82%-
Net Income Growth %44.22%-1377.12%-136.77%-
Net Income (Continuing)-43.42M-101.27M-6.86M-2.9M
Discontinued Operations0000
Minority Interest1.87M000
EPS (Diluted)-10.95-71.50-6.50-3.00
EPS Growth %66.3%-1000%-116.67%-
EPS (Basic)--71.50-6.50-3.00
Diluted Shares Outstanding3.96M1.42M1.04M894.4K
Basic Shares Outstanding3.21M1.42M1.04M894.4K
Dividend Payout Ratio----

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetMixed
Cash FlowMixed
Top Statement Risk

Persistent operating losses and volatile revenue

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Volatility Masks Weak Underlying Demand

Based on reported quarterly figures, DataMEDS AI's revenue swung from $12.4M in 2024Q4 to $1.6M in 2026Q1, a contraction that suggests the top line has not yet found a durable base.

The sequence shows revenue falling roughly 87 percent over five quarters, with year-over-year declines of 85 to 87 percent in several recent periods. The single positive quarter in 2026Q3 at $2.7M does not establish a recovery trend, and investors should monitor whether this rebound persists. Without a clear driver breakdown, the reported figures do not allow separation of volume, pricing, or acquisition effects.

Gross Margins Collapse Into Negative Territory

As reported in the income statement, gross margin moved from 13.4% in 2024Q2 to negative 9.8% in 2026Q2, indicating that direct costs have at times exceeded revenue.

Gross margin has oscillated sharply, including a negative quarter in 2025Q4 where COGS of $11.9M against $1.7M of revenue produced a gross loss of $10.3M. This pattern suggests the company may lack pricing power or has cost structures that do not scale with revenue. The volatility warrants further investigation into whether the cost base is fixed or contains one-time charges.

Operating Losses Persist Despite Scale Changes

Based on EDBL-style reported figures, DataMEDS AI posted operating losses in every one of the ten quarters, with SG&A ranging from $1.8M to $31.2M against revenue that never exceeded $12.4M.

SG&A has swung dramatically, including spikes to $31.0M in 2025Q3 and $31.2M in 2025Q1, which far exceed revenue in those periods and drove operating margins below negative 100 percent. This suggests overhead is not scaling with the business and may reflect discrete charges, though the data does not disclose their nature. Operating leverage is therefore negative in practice, and the company has not demonstrated an efficient cost base.

Net Income Diverges Sharply From Operations

According to the reported statements, net income of positive $10.6M in 2026Q3 stands against an operating loss of $3.4M, a gap that calls the quality of the reported profit into question.

A profitable net result alongside a material operating loss implies non-operating gains, tax effects, or other items not disclosed in the supplied data, and these cannot be verified from the figures provided. The EPS swing from negative 7.13 to positive 2.67 across adjacent quarters further suggests the bottom line is driven by items unrelated to core activity. Investors should treat the 2026Q3 profit as non-recurring until the drivers are explained.

Bear Case Centers on Chronic Cash Burn Risk

Based on reported figures, stock-based compensation of $25.7M in 2025Q3 and $27.8M in 2025Q1 represents a large share of operating costs, which raises the question of how much of the expense base is non-cash.

Short-seller scrutiny would likely focus on the recurring operating losses, the negative gross margins, and the dependence on large equity-based compensation that dilutes existing holders, with EPS falling to negative 31.00 in 2025Q1. Peer comparison reinforces the concern, since the healthcare services peer HCSG reports a positive operating margin of 2.6 percent while MEDS has operated at a loss throughout the period. The analysis does not establish how these losses will be financed going forward, so the sustainability of the current cost structure warrants further investigation.

MEDS — Frequently Asked Questions

Quick answers to the most common questions about buying MEDS stock.

What was DataMEDS AI, Inc.'s (MEDS) revenue in 2025?

For fiscal year 2025, DataMEDS AI, Inc. (MEDS) reported total revenue of $23.3M.

Is DataMEDS AI, Inc. (MEDS) profitable?

DataMEDS AI, Inc. (MEDS) reported a net loss of $101.3M for the fiscal year ending 2025.

What is DataMEDS AI, Inc.'s operating profit margin?

DataMEDS AI, Inc. (MEDS) reported an operating income of $-81.2M, resulting in an operating profit margin of -347.9%. This margin reflects the operational efficiency of the business before interest and taxes.

What is DataMEDS AI, Inc.'s gross profit and gross margin?

DataMEDS AI, Inc. (MEDS) generated $-9.6M in gross profit for the year, representing a gross profit margin of -41.3%. This demonstrates the company's core pricing power and production efficiency.